Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559476 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,029
- Enrollment target
NCT05559476 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,029 participants.
The verdict
NCT05559476, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,029 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Interventions
- BIOLOGICAL RSVPreF3 OA investigational vaccine
- BIOLOGICAL FLU HD vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,029 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05559476
The ClinicalTrials.gov registry entry for NCT05559476 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,029 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RSVPreF3 OA investigational vaccine is the first listed.
NCT05559476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05559476 about?
NCT05559476 is a clinical study titled "A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above". The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
What is the current status of trial NCT05559476?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,029 participants. The study started on 2022-10-20. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT05559476?
The interventions under investigation include: RSVPreF3 OA investigational vaccine (BIOLOGICAL), FLU HD vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05559476?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.